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n1033 Anticoagulant and Antiplatelet Therapy on Conckrsiorrs:These data document, for the first time, systemically en-
Unstable Angina hanced primary AG in pts with AMI and may provide new insights into
understanding of the pathogenesis of AMI.
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m103331 DelayingandPreventingIachemicEventsinPatientswithAcuteCoronarySyndromeeUsing
the PlateletGlycoproteinIlb/lllaInhibitor
Lamifiban
R.A. Barrington, D.J. Moliterno, F.van de Warf, A. Keech, N. Kleiman,
M. Bhapkar, A. Rames, M. Peek, E.J. Topol, R.M. Califf, P.W.Armstrong for
the PARAGON Investigators. Duke C/irrica/Research Institute, Durham,
NC, USA
Potent antiplatelet therapy in patients with acute coronary syndromes (ACS)
may effectively attenuate ischemic events. PARAGON A randomized 22S2
patients with unstable anginelnon-Q Ml to treatment with low or high dose
Iamifiban (LL and HL) with or without heparin (H) or atandard therapy (ST),
heparin alone. Incidence and timing (after study drug termination) of 30-day
(re)infarction (Rl) and in-hospital refractory ischemia (lSC) are displayed:
LL, H LL, noH HL, H HL, noH
(n=377) (n= 378) (n= 373) (n=396)
RI 7.7”/0 7,7”/0 9.9% 6.10/0
Isc 7.5”/0 7.7”/0 8% 9.3
RI 40hrs 59hrs 66hrs 66hrs
Timing 12,90 24,180 33,1s0 17,255
Isc 90hrs 93hrs 175 hrs 97 hre
H
(n =756)
6.2”/.
9.1”/0
53 hrs
28,236
65 hcs
Xming 22,322 20,208 49,316 43,316 20,326
LL with and without H has a favorabla effect on delaying and preventing
ischemic events in ACS patients. The effects on death and (re)Ml will require
a larger definitive trial.
m103332 AcceleratedPrimaryPlateletAggregationinAcuteMvocardialInfarction:Useofa New
Aggreg6metryEmployingLaser-LightScattering
System
K. Eto, T. Isshiki, Y. Nishiyama, S. Takeshita, M. Ochiai, T. Sate,
H. Miyaahita. Teikyo Univereiiy Hospital, Tokyo,Japan
Background: Platelet aggregation (AG) plays an important role in the patho-
genesis of acute myooardial infarction (AMI). Since tha conventional aggre-
gometry cannot identify emall aggregates, there have been coneidarable lim-
itations in detecting the early phase of AG. Aggregometry AG-10, which uses
Iaaer-lightscattering methods, is capable of identifying the temporal changes
of both the size and number of aggregates. Using this new aggregometry,
we evaluated the primary and secondary AG processes in AMI. Methods.’
Peripheral blood samples were obtained from 15 AMI patients (pts) within 3
hrs from onset, and were immediately assayed for platelet AG using AG-10
(no pts had received either anticoagulant or antiplatelet regimene prior to
sampling). Blood samples from 10 healthy volunteers were used as controls.
Results: Within the first 5 reins of AG, a marked incraase in the number of
small aggregates suggested an accelerated primary AG in AMI. In the follow-
ing 5 mlns, a modest increase in tha number of large aggregates suggested
the formation of the large aggregates (i.e. the secondary AG). As compared
to controls, AMI pts had increases in the responses of primary AG to both
epinephrine and ADP that were up to 100 times higher (EDm of epinephrfne:
0.9 vs. 102 nM, p < 0.001; ED50of ADP: 14 vs. 560 nM, p < 0.01).
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m103333 LowMolecularWeightHeparinvsRegularHeparinintheTraatmentof PatiantawithUnstableAngina
Z. Bednarkiewicz, M. Krzeminska-Pakula, M. Kurpesa, E. Trzos, J. Peruga,
W. Religa. Department of Cardiology, Medical University L6dz, Poland
The role of regular heparin [RH] as an important agent in therapy of unstable
angina [UA] is well documented but the efficacy of low molecular weight
heparin [LMWH] in these patients is still unclear. The aim of our study was to
assess results of LMWH therapy in comparison to RH treatment in patienta
[pts] with UA. Study population consisted of 176 pte with UA defined es
episodes of chest pain lasting <20 min and/or with ST changes during 12
hours before start of treatment. Pts were divided into two groupa [GR]: GR I -
74 pts received LMWH (Fraxiparine) in doae 250/kg/day/i.v.; GR II -102 pts
received RH in APTT adjusted. Pts wera also treated with nitratea, aspirin,
beta-blockers and/or calcium channel. Baseline clinical data of groups were
comparable. During hospitalisation end points: death, myocardial infarction
[Ml] were asseesed. Also frequency of: positive results of treatment IPRTl,
emergency angiography [EA] and emergency PTCA or CABG [EPT/CABG]
and bleeding complication [BC] during therapy were estimated. As PRT
considered stabilisation of symptoms and ecg without CK elevation during
46 hrs after start of therapy, Resu/ts:
Group I-LMWH Group 11-RH P
Death [“Aof Dtsl 1,4 1.9 NS
Ml [“A :f pts] 13.5 17.5 <0.01
PRT [% of pts] 74.3 72.7 NS
E’ [“Aof pts] 20.2 24.5 <0.01
EPT/CABG [% of pte] 13.5 15.6 NS
8C [“AOfDtd 1 .2 4.9 <0.01
Conclusions: LMWH seems to be useful in the therapy pts with UA.
In pts receiving LMWH the ratio of subsequent myocardial infarction and
urgent coronary angiography was lower and bleeding mmplieations were
less frequent.
I 1033-34 I Relationshipof OutcomeatoTreatmentwith
Lamifibanin Patients Undergoing PTCA: Analysis
of PARAGON A
J.H. Alexander, L.K. Newby, D.J. Moliterno, M. Bhapkar, F. Van de Werf,
H.D. White, R.A. Barrington, E.J. Topol, R.M. Calif for the PARAGON A
Investigators. Duke University Medical Centec Durham, NC, USA
Previous studies of GP llb/llla inhibitors in patients with, acute Coronary
syndromes undergoing PTCA demonstrated a reduction in death and Ml.
In PARAGON A 306 patients (13.6%) underwent PTCA. We assessed the
relationship betwean deatWMl and a safety composite (SFCOMP = stroke/>
modarete bleedingkhrombocytopenia) and treatment with the non-peptide
GP llb/lila blocker, Iamifiban at high (HL) or low (LL) dose with or without
heparin (H), or standard therapy (ST= haparin and ASA). Resulte are shown
below.
LL,H LL,–H) HL,H HL,–H ST
(n =373) (n= 375) (n =370) (n =390) (n= 749)
PTCA 11.6”/0 13.6% 11.4°A 12.6°A 16.0%
lime (h)* 4al 41.5 4a8 67,8 35.0
DeatWMl 6.8”/0 11.80/. 16.7°A 14.3”/0 15.6”/6
SFCOMP 9.5”/. 4.1% 14.3”/0 12.8”A 6.6%
*Time = mediantime from end of infusionto PTCA
Conckrsiom Treatment with Iamifiben may delay and reduce the use
of PTCA in patients with unstable angincdnonQ Ml. Outmmes in patients
undergoing PTCA who receive potent platelet inhibition compara favorably
to those receiving standard therapy. Use of HL confers no additional benefit
over LL but carries additional risk.
